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1. Summary 
 
Successive cancer policy documents have emphasised the role high quality intelligence about cancer 
services can play in improving clinical quality and encouraging scrutiny of clinical performance. Measuring 
variations in outcomes can contribute to enhancing quality by motivating and empowering clinicians to 
improve care. As a result we were commissioned by the National Cancer Action Team to identify, develop 
and test a suite of nurse-sensitive indicators that could contribute to the effective monitoring and quality 
improvement of chemotherapy services.  Building on our earlier review, this report presents findings from 
the second phase of work aimed at developing and testing the proposed set of indicators in a small 
number of pilot sites.  
 
The dimensions of quality covered by the nurse-sensitive indicators include: 
  severity of subjective symptoms resulting from treatment, across a range of domains, including 
those that we identified as most sensitive to the quality of nursing services (nausea, vomiting, oral 
problems) 
  perceptions of assessment, information and support to manage symptoms offered to patients by 
nurses who administer chemotherapy (support for self-care) 
  safety of drug administration (extravasation and pain at infusion site) and  
  patient experience of the administration process and informational support.  
Specifications for each indicator were drafted and a data collection plan developed. Data on some of the 
indicators are routinely recorded (e.g. extravasations), however indicators in the effectiveness and 
experience domains are subjective experiences (e.g. symptom severity) and unlikely to be routinely 
recorded in a standard form.  Because of this we decided that a major focus of the project had to be the 
design and development of a method for collecting such information and so we drafted a self-assessment / 
self-report questionnaire that patients could complete with each cycle of chemotherapy. We also identified 
workforce and contextual information that is likely to influence outcomes on the indicators. 
 
The nurse sensitive indicators were piloted in ten cancer centres across England over a 12 week period. 
Patients attending for ambulatory chemotherapy were asked to complete the self-report questionnaire at 
each visit during the data collection period. Data were analysed to explore variability in scores between 
centres and were also adjusted for casemix. The indicator system that we have designed and reported 
here has real potential to be used now for local quality improvement efforts and for benchmarking between 
centres. We have shown substantial levels of adverse symptoms, large numbers of patients who perceive 
that support to manage symptoms could be better and unexplained variation between centres which all 
suggestion potential for improvement. Stakeholders in our pilot sites gave a clear indication of the potential 
to use these indicators to stimulate and evaluate quality improvement. 
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2. Background 
 
Equity and excellence: Liberating the NHS [1] identified the central role that measurement of quality will 
play in driving improvement, productivity and efficiency in the NHS. „Improving Outcomes: A Strategy for 
Cancer [2] reiterated the focus on delivery of critical outcomes rather than measuring the process by which 
outcomes are delivered. The success of this strategy will rely on high quality data that encompasses three 
domains of quality (our emphasis): 
  the effectiveness of treatment and care provided to patients – measured by both clinical outcomes 
and patient-reported outcome measures (PROMS) 
  the safety of the treatment and care provided to patients 
  the broader experience patients have of the treatment and care they receive. 
[1](p.22) 
 
In cancer care the delivery of chemotherapy is changing to a situation where most is delivered in an 
ambulatory setting [3]. A recent report from the National Confidential Enquiry into Patient Outcomes and 
Death (NCEPOD) [4] highlighted concerns about the wide variation in quality and safety of chemotherapy 
services across England. This is supported by more recent findings from the 2010 National Cancer Patient 
Experience Survey which showed there was significant variation in the proportion of patients who felt that 
staff did everything possible to control the side effects of chemotherapy [5]. While in some Trusts all 
patients felt everything possible was being done, in others as many as 40% did not. Similar findings were 
also reported with regards to emotional support with significant variation also associated with different 
cancer diagnoses within the same Trust.  
 
In the national survey patients who reported being cared for by a Clinical Nurse Specialist were 
significantly more likely to be positive about their care and treatment on a range of factors. This suggests 
nurses play a very influential role in patients‟ experience of cancer care.  Other evidence points to the 
potential for nurses to influence the effectiveness and safety of care, in particular in minimising the 
symptoms and harms associated with cancer chemotherapy [6]. This effect is likely to be heightened in a 
nurse-led care environment, typified by the ambulatory chemotherapy setting.  
 
There has been specific interest in developing metrics that more closely reflect the contributions of the 
whole clinical team [2, 7]. This commitment has been reiterated in relation to the nursing contribution in 
„Front Line Care‟ [8] and „The Nursing Roadmap for Quality‟ [9].  „A High Quality Workforce‟ [7] signalled 
the development of a suite of metrics for care outcomes influenced by nurses as part of a range of 
measures that pertain to the whole clinical team. Development of these nurse sensitive indicators is 
progressing but the areas covered e.g. pressure ulcers, while of wide applicability, do not focus on core 
dimensions of quality in nursing services for specialist services, such as cancer care, particularly outside of 
an inpatient environment.  
 
Successive cancer policy documents [2, 10] have emphasised the role high quality intelligence about 
cancer services can play in improving clinical quality and encouraging scrutiny of clinical performance. 
Measuring variations in outcomes can contribute to enhancing quality by motivating and empowering 
clinicians to improve care. As a result we were commissioned by  the National Cancer Action Team 
(NCAT) to identify, develop and test a suite of nurse-sensitive indicators that could contribute to the 
effective monitoring and quality improvement of chemotherapy services alongside other methods, for 
example the Cancer Services Peer Review process.   
 
A first phase of work aimed to assess the evidence for various indicators and identify a small number of 
priority areas for development of a pilot system [6]. A series of scoping reviews were undertaken and a 
number of clinical experts consulted. As a result a shortlist of 11 potential outcome areas was identified. Nurse Sensitive Indicators   2011 
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Overall, although a large number of potential outcomes were identified the evidence to support a link 
between nursing services and outcomes was often relatively weak. Where evidence did exist that an 
outcome might be attributable to nursing input, the precise nursing role in achieving the outcome was often 
unclear.   
 
The clearest case for the direct impact of nurses in the ambulatory cancer chemotherapy setting related to 
the safety and experience dimensions of quality. Cancer nurses‟ impact on treatment effectiveness (in 
terms of successful treatment of the underlying condition) was indirect and mediated through their ability to 
support patients in managing toxicities from treatment including symptoms [6]. 
 
No detailed, readily available specifications for quality indicators were identified. It was recommended 
nurse-sensitive indicators covering each of the three domains of quality: safety, effectiveness and 
experience be developed  
 
1)  Effectiveness (symptom control): nausea and vomiting  
2)  Safety: chemotherapy administration 
3)  Experience of care 
 
In developing quality indicators for chemotherapy nursing teams the aim is to identify measures that relate 
to important outcomes that are not just known to be sensitive to the contribution of nursing but which also 
fulfil a range of other criteria. Key features of successful indicators are that they measure important 
phenomena, are scientifically sound, provide useable information and are feasible to collect [11]. Where 
comparative performance measures are required, either to benchmark local performance against others 
for quality improvement or for external comparison purposes, any indicator system would need to permit 
risk adjustment for key mediating/confounding factors. For example the severity of symptoms experienced 
is likely to be dependent upon chemotherapy regimens delivered and potentially other patient factors.  
 
Building on our review, this report presents findings from the second phase of work aimed at developing 
and testing the proposed set of indicators in a small number of pilot sites.  
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3. Aims and objectives 
 
The aim of this project was to identify, develop and test a suite of nurse-sensitive indicators that could 
contribute to the effective monitoring of chemotherapy services. Specific objectives were as follows: 
1.  To develop an instrument to collect data to monitor performance of nurse-sensitive outcome 
indicators 
2.  To evaluate the feasibility, utility and acceptability of monitoring nurse-sensitive outcome indicators 
in clinical practice in a small number of pilot sites across England 
3.  To undertake preliminary validation of the nurse-sensitive outcome indicators 
4.  To determine the necessity for, and practicality of, risk adjustment for patient and treatment factors 
5.  To gather data on contextual factors that may moderate the effectiveness of nursing e.g. skill mix, 
staffing levels  
6.  To create a toolkit to support the use of nurse-sensitive outcome indicators in practice 
 
All stages of the project were supported by a number of reference groups.  
  Clinical reference group (CRG): This consisted of clinicians from the pilot sites (see Appendix A for 
full list) who provided insight into the practical aspects of the measurement system and its 
implementation 
  User Reference Group (URG): A patient reference group was convened at the preliminary pilot 
site consisting of people with cancer who completed chemotherapy within the previous 12 months. 
This group assisted with assuring the relevance and importance of the domains selected for 
piloting and in particular the patient experience domain 
  Technical reference group (TRG): International experts on patient safety, measuring symptom 
intensity, developing and testing patient reported outcomes measures and measuring patient 
experience were consulted (see Appendix B for full list). The primary purpose of this group was to 
advise on the technical specification of the selected outcomes   
 
Development and testing of the nurse-sensitive outcome indicators was an iterative process whereby a 
number of overlapping pieces of work were undertaken as shown in Figure 3.1.  
 
The project was undertaken in partnership with five specialist regional centres across England:  
  Clatterbridge Centre for Oncology NHS Foundation Trust  
  Guy‟s & St Thomas‟ NHS Foundation Trust 
  Sheffield Teaching Hospitals NHS Foundation Trust  
  Southampton University Hospitals NHS Trust  
  St Helen‟s & Knowsley Teaching Hospitals NHS Trust 
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As all the partners were specialist regional centres we added a number of smaller units to represent a 
spectrum of size of unit and likely complexity of care delivered from the North Trent Cancer Network 
(NTCN) which provided satellite services to the oncology service at Sheffield Teaching Hospitals NHS 
Foundation Trust. They were:  
  Barnsley NHS Foundation Trust 
  Chesterfield Royal Hospital NHS Foundation Trust 
  Doncaster & Bassetlaw Hospitals NHS Foundation Trust 
  Rotherham NHS Foundation Trust 
 
 
Figure 3.1: Project stages 
 
 
 
NSI = nurse sensitive indicators 
 
 
 
Develop NSI 
Amend data  
collection procedures 
Amend NSI  
Conduct pre-pilot     to assess feasibility  
and acceptability 
Agree data  
collection  
procedures 
Conduct pre pilot  
to assess NSI  
feasibility and acceptability 
Create toolkit  Conduct pilot  
to assess NSI  
feasibility and validity 
URG 
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4. Stage One: Initial development 
 
4.1 Developing nurse sensitive indicators 
 
Based on the results of our phase one work [6], we presented a list of outcome domains and candidate 
indicators to the Clinical Reference Group to identify potential indicators that met the criteria of: 
  Addressing an important topic 
  Scientifically valid (including sensitivity to quality of nursing services) 
  Possible and practical to collect meaningful data 
Source:[12] 
 
The reference group was encouraged to make suggestions for changes and additions with these principles 
in mind. An iterative process was adopted whereby the clinical reference group independently rated the 
nurse sensitive outcome indicators selected using the criteria outlined above and suggested further 
amendments/improvements.   
 
Tables 4.1-4.3 present the indicators considered during the first phase of the project. The tables include 
the rationale for including the indicator and what the Clinical Reference Group thought about it in terms of 
its acceptability, feasibility and interpretability. The final column shows whether at this stage the indicator 
was selected for further consideration.  
 
Specifications for each indicator were drafted (see Appendices C-E) that included:  
  definition 
  rationale 
  factors the indicators may be sensitive to (other than nursing behaviours/quality) 
  potential data sources and assessment of their quality 
  potential implementation issues.  
 
A key aspect of selecting and drafting the specifications involved consideration of available data. Data on 
some of the indicators related to safe drug administration are routinely recorded (e.g. extravasations). 
Indicators in the effectiveness and experience domains are subjective experiences (e.g. symptom severity) 
and unlikely to be routinely recorded in a standard form.  Because of this we decided that a major focus of 
the project had to be the design and development of a method for collecting such information. We decided 
that a patient completed self-assessment / self-report instrument was the most practical approach to 
gathering valid data. 
 
We therefore drafted a self-assessment / self-report questionnaire that patients could complete with each 
cycle of chemotherapy. We based the symptom assessment on the widely used Chemotherapy Symptom 
Assessment Scale [C-SAS, 13] [13]. We included specific items about information and advice to support 
self-care for nausea and vomiting and more general questions about experiences of care received in the 
ambulatory chemotherapy setting which were adapted from questions used in national patient surveys [5, 
14, 15]. These were adapted to focus on the specific care setting and the input of nurses. We also asked 
about perceived safety, using items from Schwappach and Wernl [16]. 
 
Because we recognised that case mix adjustment would be necessary we also sought information about 
class of chemotherapy received, mode of drug administration, age and gender. Discussion with the Clinical 
Reference Group revealed that the participating centres did not have resources to audit patients‟ medical 
records to readily provide this information. Therefore this was gathered from patients as they completed 
the self-report instrument.  Nurse Sensitive Indicators   2011 
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Table 4.1: Safety – chemotherapy administration  
 
Suggested measure    Source of data  Rationale  CRG Notes  Selected 
Incidence of extravasation of 
cytotoxic drug per 1000 
treatment cycles 
*  All reported incidents 
of extravasation  
Indicator of poor clinical practice - /stressed 
overstrectched or inexperienced nurses 
Potential underreporting 
How to classify suspected extravasation 
Needs risk adjustment for regimen 
Can be moderated by damage limitation actions (e.g. flushing procedures, 
administration of antidote) 
Y 
Extravasation resulting in 
ulceration per 1000 treatment 
cycles 
*  All reported incidents 
of extravasation 
Rare but late indicator of unsafe practice  Potential underreporting 
Needs risk adjustment for regimen 
Y 
Pain or irritation at the 
infusion site per thousand 
cycles 
*  Patient self report  Can be caused by the speed of administration therefore 
indicator of poor practice or poor access to central line 
service 
Potential recall bias 
Can occur during and after chemotherapy administration so time period patients 
asked to review important (e.g. time of infusion, 7 days, previous cycle) 
Needs standard mechanism for recording and collating  
Needs risk adjustment for chemotherapy agent 
Y 
Drug administration errors  *  Safety reporting 
systems 
Indicator of poor clinical practice  Unclear the extent to which available measures relate to nursing role 
Potential underreporting 
Personnel classifications vary on incident forms 
Drugs errors may not be reported by the person who made the error 
N 
Nurse assessment of venous 
integrity 
$  Patient record  Require prior to each treatment cycle to ensure 
appropriate route of chemotherapy administration 
Potential negative rather than positive recording in patient records  
Potential process measure 
Y 
Change in route of 
chemotherapy administration 
(eg from intravenous to PICC 
or central line) 
$  Patient record  Ensure appropriate route of chemotherapy 
administration 
 
Potentially unreliably recorded in patient records 
Availability of skilled personnel/radiology time for insertion of central lines 
How to account for patient and professional preference 
 
Y 
Planned dose on time  $  Electronic prescribing 
system 
For adjuvant treatment is an indicator of treatment 
efficacy 
How to account for patient and professional preference 
 
Y 
Patient perceptions of safe 
medicine administration 
$  Patient report  
 
Insight into detailed processes of care not routinely 
collected elsewhere 
Ambiguous phrasing of some questions 
How to account for individual personality differences 
Questionable whether patients can properly judge important aspects of safety 
Items not relevant to safe chemotherapy drug administration e.g. ensuring 
venous patency, correct IV flow rate, observation of infusion site etc 
Y 
*Indicator generated from Phase 1 [6]    $ Indicator generated from Clinical Reference Group  
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Table 4.2: Effectiveness - Nausea and vomiting 
 
Suggested measure    Source of data  Rationale  CRG Notes  Selected 
Documented assessment of 
severity of nausea and 
vomiting (% per cycle) 
*  Clinical audit record   Presumed link between assessment and management 
of symptoms 
 
Documented assessment does not necessarily lead to improved outcomes 
Potential unreliability of recoding in patient records 
Potential negative rather than positive recording in patient records  
Process outcome 
Time consuming and costly to undertake 
N 
Patients reporting nausea 
following treatment (% per 
treatment)  
*  Patient self report  Detects severity and distress associated with nausea  Requires a standard mechanism for recording. 
Needs risk adjustment for regimen 
Exclude prior to cycle 1 
Y 
Patients reporting vomiting 
following treatment (% per 
treatment)  
*  Patient self report  Detects severity and distress associated with vomiting  Requires a standard mechanism for recording. 
Needs risk adjustment for regimen 
Exclude prior to cycle 1 
Y 
*Indicator generated from Phase 1[6]    $ Indicator generated from Clinical Reference Group  Nurse Sensitive Indicators   2011 
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Table 4.3: Patient experience 
 
Suggested measure    Source of data  Rationale  CRG Notes  Selected 
Confidence and trust  *  Patient self report  Key indicator of a good patient experience  Needs to be specific to chemotherapy nurses  Y 
Communication   *  Patient self report  Key indicator of a good patient experience  Needs to be specific to chemotherapy nurses  Y 
Ability to get answers to 
questions 
*  Patient self report  An aspect of communication and therefore a key 
indicator of a good patient experience 
Needs to be specific to chemotherapy nurses 
Key issue is information given being in way that patients can understand 
N 
Information about appropriate 
self-care 
*  Patient self report  An aspect of communication and therefore a key 
indicator of a good patient experience 
Needs to be specific to chemotherapy nurses  Y 
Emergency contact details 
$  Patient self report  Important specific information which needs to be 
communicated 
Needs to be specific to chemotherapy nurses 
Process indicator 
Y 
Information on what to expect 
$  Patient self report  An aspect of communication and therefore a key 
indicator of a good patient experience 
Needs to be specific to chemotherapy nurses  Y 
Nurses Rushed during 
treatment 
$  Patient self report  Known to deleteriously affect patients experiences  Needs to be specific to chemotherapy nurses  Y 
Not wasting time 
$  Patient self report  Known to deleteriously affect patients experiences    Y 
Privacy 
$  Patient self report  An aspect of communication and therefore a key 
indicator of a good patient experience 
Needs to be specific to chemotherapy nurses  Y 
Nurses technical skills 
$  Patient self report  An aspect of confidence and trust and therefore a key 
indicator of a good patient experience 
Needs to be specific to chemotherapy nurses  Y 
Receive chemotherapy in 30 
mins of arrival 
$  Patient self report  As wasting time above  Process outcome  Y 
Nurses and doctors work 
together 
$  Patient report  Continuity of care is a key indicator of patient 
satisfaction  
How will they judge it?  Y 
Communication with family 
$  Patient report  An aspect of communication and therefore a potential 
indicator of a good patient experience 
Patient may not know  Y 
*Indicator generated from Phase 1[6]    $ Indicator generated from Clinical Reference Group  Nurse Sensitive Indicators   2011 
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We included a list of drugs based on classifications of extravasation risk (http://extravasation 
.org.uk/table.htm) and those known to be a high risk for causing vomiting [17]. Extravasation risk was 
classified as follows. The higher the grouping, the higher the risk of causing severe and serious tissue 
damage: 
  Group 5: Vesicants 
  Group 4: Exfoliants 
  Group 3: Irritants 
  Group 2: Inflammitants  
  Group 1: Neutrals – only cyclophosphamide >1500mg included from this group 
 
During this phase we also identified workforce and contextual information that would be required. 
 
We undertook preliminary testing of the indicators with members of a patient reference group (n=9) who 
worked with one of our collaborating centres. They were asked to complete the questionnaire and 
comment on: 
  difficulties in understanding the questions 
  ease of completion 
  appearance  
  willingness to complete the measure with each cycle of chemotherapy 
  potential improvements 
 
On the whole the respondents found the questionnaires easy to answer and completion took 
approximately 10-15 minutes. They all said they would be willing to complete it each time they received 
chemotherapy, although one said they would only do it if it was used to guide care delivery.  
 
In order to focus closely on patient experience that was most important to patients we also conducted 
five detailed individual interviews. This provided us with an in depth understanding of patients‟ 
perspectives so that we could develop the right questions for the self-report/self-assessment 
questionnaire to assess what it is the chemotherapy nurses did and said that promoted a positive 
experience of receiving chemotherapy. 
 
On the basis of the feedback gathered during this phase of the project the content of the self-report 
measure was finalised. Appendix F provides details on the decision-making process and Table 4.4 
outlines the items included. The main alterations to the measure were: 
1.  to add extra symptoms to the effectiveness domain, so that it was more comprehensive as the 
absence of some symptoms appeared to negate their importance 
2.  to remove the patient-reported items on perceptions of safe medicine administration because of 
lack of clarity on the meaning of  subjective experiences of objective safety behaviours. 
3.  to reduce the number of items overall and shorten completion time 
4.  to reduce / avoid overlap with items covered by national surveys 
5.  to focus on elements of experience that were related to supporting self-care or were most 
strongly endorsed as important but problematic by patients 
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Table 4.4: Modifications to items on the self-report measure 
 
Initial items  Added / adapted during development  Selected? 
Safe medicine administration 
Incidence of extravasation of cytotoxic drug/1000 
treatment cycles 
  √ 
Extravasation resulting in ulceration/1000 treatment 
cycles 
  √ 
Pain or irritation at the infusion site per thousand cycles    √ 
Nurse assessment of venous integrity     
Change in route of chemotherapy administration     
Planned dose on time     
Patient perceptions of safe medicine administration     
Effectiveness 
Patients reporting severe nausea following treatment 
(%/treatment) 
  √ 
Patients reporting severe vomiting following treatment 
(%/treatment) 
  √ 
  Patients reporting severe problems with mouth or throat 
following treatment (%/ treatment) 
√ 
  Patients reporting feeling severely weak  following 
treatment (% per treatment) 
√ 
  Patients reporting feeling severely weak  following 
treatment (%/treatment) 
√ 
  Patients reporting feeling severely tired  following 
treatment (%/ treatment) 
√ 
  Patients reporting feeling severely low or depressed  
following treatment (%/ treatment) 
√ 
Patients reporting nurses ask about symptoms    √ 
Patients reporting nurses provide practical advice about 
managing symptoms 
  √ 
  Patients reporting  nurses ask about severity of symptoms  √ 
  Patients reporting  nurses useful information of symptoms  √ 
  Patients reporting  Confidence to manage symptoms  √ 
Experience of process of care 
Confidence and trust     
Communication     
Information about appropriate self care     
Information on what to expect   Information on what to expect with oral chemotherapy  √ 
Rushed during treatment    √ 
Unnecessary time waiting    √ 
Privacy     
Nurses skilled and gentle at cannulation    √ 
Receive chemotherapy in 30 minutes of arrival     
Nurses and doctors work together     
Communication with patient    √ 
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The final set of indicators cover  
  severity of subjective symptoms resulting from treatment, across a range of domains, 
including those that we identified as most sensitive to the quality of nursing services (nausea, 
vomiting, oral problems)  
  perceptions of assessment, information and support to manage symptoms offered to patients 
by nurses who administer chemotherapy (support for self-care) 
  safety of drug administration (extravasation and pain at infusion site) and  
  patient experience of the administration process and informational support  
 
Completion time was reduced to 5 minutes which we judged to be more acceptable for a questionnaire 
that was to be completed every 3-4 weeks (depending on treatment regimen).  
 
 
4.2. Development of the data collection plan 
 
As electronic systems varied across sites and were not generally used routinely to assess patient 
symptoms, a pen and paper based system was adopted. We envisaged that effectiveness indicators 
would be completed prior to each cycle of chemotherapy and that chemotherapy nurses would use them 
to guide the clinical assessments they make. Thus they would be used repeatedly with patients to 
explore change over time. Whilst symptoms may vary between cycles and could be phrased in a 
manner which could be asked at each cycle, this was more problematic with some aspects of 
experience of care. Thus we identified some of the experience indicators that would be completed only 
once during the course of chemotherapy. 
 
The data collection plan we developed was informed by a detailed site visit to Southampton University 
Hospitals NHS Trust in which we mapped the flow of patients through the chemotherapy day centre in 
order to identify the best way of approaching patients so the maximum number completed the self-
report/self-assessment questionnaire. Moreover we were mindful of the need to minimise the impact of 
data collection on chemotherapy day centre staff. In brief, the resulting data collection procedure was as 
follows: 
  On arrival at the chemotherapy day centre reception staff would ask all patients to complete the 
self-report questionnaire 
  Patients to return completed self-report questionnaire in a receptacle in the patients waiting 
area 
  Local project lead to collect extravasation and contextual data weekly  
 
At the same time a toolkit was developed to aid data collection. This outlined key tasks that needed to 
be performed and included a number of resources including a script for staff to use when approaching 
patients, a sheet on which to record reasons for non-completion, a weekly checklist for contextual data 
collection. 
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5. Stage Two: Pre piloting 
 
The key task of this phase was to pilot data collection in a single centre so as to: 
  assess the feasibility of asking patients to complete the questionnaire when they attend for 
chemotherapy  
  monitor the data returns to identify potential problems  
  make a preliminary assessment of the sensitivity and variability of the indicators 
  assess the relevance and feasibility of collecting workforce and contextual information 
  amend the toolkit as necessary 
 
The preliminary pilot study was undertaken at Southampton University Hospitals NHS Trust over a week 
period (4/10/10 – 8/10/10). The self-report questionnaire was given to patients by receptionists as they 
checked into the chemotherapy day suite.  
 
 
5.1 Results 
 
Ninety-two patients were eligible to participate and of these 68 (74%) returned the self-report 
questionnaire. A heterogeneous sample was recruited in terms of sex, age, treatment cycle and class of 
chemotherapy drug received. The incidence of extravasation and ulceration caused by extravasation 
was zero.   
 
Missing data varied according to the question being asked. For example 4% of people did not record 
which age band they fell into and 13% did not report the cycle of treatment. Across all items on the 
outcomes a quarter of respondents (24%) did not answer at least one question.  
 
Overall levels of severe symptoms experienced were relatively low although substantial numbers did 
experience at least moderate symptoms for all areas assessed. More than 20% of patients reported 
experiencing moderate or severe tiredness, weakness and nausea. When patients were asked to rate 
what they perceived chemotherapy nurses did to manage their symptoms almost 30% said that nurses 
did not ask about whether they were experiencing symptoms and a similar number reported nurses 
were not aware of the severity of their symptoms. A smaller proportion felt that the nurses were not 
providing useful support for symptom management. In relation to other aspects of experience there was 
also significant variation on most items. Almost 20% of patients receiving oral chemotherapy said the 
chemotherapy nurses did not ask whether they felt able to manage. The majority said that to some 
extent at least they spent an unnecessary amount of time waiting for their treatment. 
 
Respondents used the full range of scores for each item. A small number of changes were made to the 
questionnaire and these are indicated in Appendix F. The final version of the self-report questionnaire 
employed in stage three can be found in Appendix G. A number of minor amendments were also made 
to the toolkit. 
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6. Stage Three: full pilot testing  
 
The final phase of the project aimed to  
  test the feasibility, acceptability and utility of the indicators 
  refine specifications of the indicators 
  evaluate methods for providing feedback to centres 
  amend the toolkit to incorporate lessons learnt from using the indicators in practice 
  make recommendations for future development and use of the indicators 
 
The main pilot study commenced in 15th November 2010 and continued till 18th March 2011. Each site 
was asked to run the pilot for 12 weeks. All measures were professionally printed and despatched to 
centres along with other relevant documentation. A member of the project team visited each site to 
familiarise staff with the indicators and the procedures for data collection. It was recommended that a 
project lead be identified at each site to act as a local champion and drive the project forward. Once 
data collection was underway the project team provided regular support via email/phone contact. Each 
week centres were asked to return data (completed self-report questionnaires, rates of extravasation 
and resulting ulceration, numbers treated, reasons for non-completion, staffing levels/skill mix and use 
of acute oncology services). 
 
Measures were distributed to all patients by reception staff in the ambulatory chemotherapy areas. An 
exception was patients attending for their first treatment as they would not be able to reflect on their 
previous cycle of treatment. Those administering the self-report questionnaire were asked to note any 
reasons for non-completion so the acceptability of the measure could be assessed. The total number of 
patients treated each week who were eligible to complete the measure was used to calculate the 
response rate. 
 
Mid way through data collection and at the end of the project, the project leads were sent a copy of the 
results, in the same format as Charts 6.1-6.5. Whilst they were informed of the code letter for their 
centre, results for the other centres remained anonymous. Thus they were able compare their results 
with those of other centres. 
 
We formally assessed the experiences of staff by means of qualitative interviews either face-to-face or 
over the phone with the project lead at each participating centre to explore their assessments of data 
quality and the burden of data collection (see Appendix H for topic guide).  
 
 
6.1 Results 
 
Centres were asked to recruit for 12 weeks however few achieved this. The main reasons being poor 
weather conditions during December 2010 and staffing/scheduling issues over the Christmas period. 
Figure 6.1 outlines the flow of patients through the study.  
 
In total 2564 completed self-report questionnaires were returned, however 98 were excluded as patients 
were receiving their first cycle of chemotherapy. Therefore analysis was conducted on 2466 self-report 
questionnaires. It should be noted that patients may have completed the outcome measure repeatedly 
and so it is likely that the number of people participating is less than the number of questionnaires 
returned.  
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Figure 6.1: Flowchart of recruitment 
 
 
 
 
 
6.1.1 Participation rate 
 
The sampling frame could not be precisely enumerated, as centres were able to provide us with 
estimates of patients currently receiving treatment over the data collection period but not cycles of 
treatment administered during periods when the questionnaire was being distributed. 
 
Overall we achieved a response rate of 38% (that is an average of 0.38 responses per potentially 
eligible patient during the12 week pilot period). The response rate varied widely between centres with 
the lowest being 10% while one centre achieved a rate of over 161% (that is an average of 1.61 
responses per patient). However, as we know that questionnaires were not offered to all patients and 
data was not collected for the full period in all centres, thus reducing the number of potential number of 
administrations, it is clear that this substantially underestimates the true response rate. We also 
calculated a response rate based on the number of patients we knew had been approached: that is 
where a questionnaire was returned or a response of ineligible or declined was recorded. Using this rate 
gave response rates of between 40% and 87%, with most centres achieving over 70%. As data on 
eligibility or refusal to participate may not have been consistently collected this could be an overestimate 
for some centres (Table 6.1). 
 
 
7164 received 
chemotherapy 
 
2564 completed 
NSI questionnaires 
 
389 ineligible 
821 declined 
3969 not accounted for 
2466 completed 
NSI questionnaires 
 
98 receiving first 
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Table 6.1: Response rates by site 
 
   J  K  L  M  N  P  Q  R  S*  T   All 
Patients receiving chemotherapy (n)  2464  140  244  187  153  593  706  487  402  1788  7164 
Questionnaires completed (n)  250  30  117  154  191  522  126  737  85  352  2564 
Ineligible patients (n)  60  8  18  22  20  74  85  33  -  69  389 
Declined participation  98  9  19  119  45  93  188  115  -  135  821 
Number of patients unaccounted for  2172  93  166  141        307  198  -  1232  3969 
Rate for all patients  
(those known to be ineligible)  10%  23%  52%  93%  144%  101%  20%  162%  -  20%  38% 
Rate among known approached   72%  77%  86%  56%  81%  85%  40%  87%  72%  72%  76% 
*combined with Centre T 
 
 
The personal characteristics of the sample are shown in Table 6.2. More men than women were 
recruited to the study, particularly at Centres K and P, although this was not the case across all centres. 
Of those recruited 53% were aged between 50-70 years and for all but one of the centres the proportion 
ranged from 53% to 61%. Whilst fewer (34%) were recruited from this age band at Centre J, this figure 
may not be accurate as 34% of participants did not provide this information. Ninety per-cent of the 
sample identified themselves as being of white ethnicity. The only centres that recruited a greater 
proportion of people from Black and minority ethnic backgrounds were Centres S (26%) and T (32%).  
 
For the whole sample, 33% chose not to provide information on their cancer diagnosis although this rate 
varied across centres. Thus whilst only 13% of cancer diagnoses were missing at Centre Q, 50% were 
missing from Centre J. Of those who provided diagnostic information (n =1664) 46% were diagnosed 
with either breast, colorectal, lung, gynaecological or haematological cancers and almost half of these 
had a breast cancer diagnosis (48%). The types of cancer recruited varied between centres, for 
example Centre K only recruited people being treated for breast cancer and Centre S mainly recruited 
those with colorectal cancer. A wider variety of cancer diagnoses were reported from centres that 
recruited larger numbers (J, P, R, T). See Table 6.3. Full details are shown in Appendix I. 
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Table 6.2: Personal characteristics  
 
Centre  J  K  L  M  N  P  Q  R  S  T  Total 
N  250  30  117  154  191  522  126  737  85  352  2466 
Sex N (%) 
Male 
Female 
Missing 
 
49 (20) 
92 (38) 
99 (41) 
 
18 (62) 
6 (21) 
5 (17) 
 
52 (44) 
48 (41) 
17 (15) 
 
56 (37) 
66 (44) 
29 (19) 
 
82 (44) 
73 (40) 
30 (16) 
 
279 (55) 
135 (27) 
93 (18) 
 
51 (45) 
57 (50) 
5 (4) 
 
317 (45) 
249 (35) 
142 (20) 
 
36 (42) 
26 (31) 
23 (27) 
 
121 (36) 
128 (38) 
86 (26) 
 
1061(43) 
880 (36) 
525 (21) 
Age N (%) 
18-30 
31-40 
41-50 
51-60 
61-70 
71+ 
Missing 
 
2 (1) 
8 (3) 
21 (9) 
34 (14) 
48 (20) 
46 (19) 
81 (34) 
 
- 
5 (17) 
5 (17) 
6 (21) 
11 (38) 
2 (7) 
- 
 
2 (2) 
9 (8) 
12 (10) 
29 (25) 
37 (32) 
23 (20) 
5 (4) 
 
    7 (5) 
    7 (5) 
21 (14) 
44 (29) 
49 (32) 
17 (11) 
6 (4) 
 
4 (2) 
4 (2) 
24 (13) 
34 (18) 
77 (42) 
39 (21) 
3 (2) 
 
4 (1) 
24 (5) 
99 (19) 
129 (25) 
159 (31) 
79 (17) 
13 (3) 
 
1 (1) 
7 (6) 
14 (12) 
32 (28) 
37 (33) 
20 (18) 
2 (2) 
 
2 (<1) 
32 (4) 
113 (16) 
220 (31) 
174 (25) 
151 (21) 
16 (2) 
 
2 (2) 
1 (1) 
9 (11) 
24 (40) 
15 (19) 
22 (27) 
8 (1) 
 
9 (3) 
17 (5) 
53 (15) 
83 (24) 
101(29) 
58 (17) 
31 (9) 
 
32 (1) 
113 (5) 
368 (15) 
630 (25) 
702 (28) 
456 (19) 
165 (7) 
Ethnicity N (%) 
White  
Mixed 
Asian 
Black 
Chinese 
Other  
Missing 
 
154 (64) 
- 
1 (<1) 
2 (1) 
- 
1 (<1) 
82 (34) 
 
29 (100) 
- 
- 
- 
- 
- 
- 
 
 
112 (96) 
- 
- 
- 
- 
- 
5 (4) 
 
144 (95) 
1 (1) 
1 (1) 
- 
- 
- 
5 (3) 
 
 
176 (95) 
- 
2 (1) 
2 (1) 
- 
 
5 (3) 
 
488 (96) 
- 
6 (1) 
2 (<1) 
1 (<1) 
- 
10 (2) 
 
113 (100) 
- 
- 
- 
- 
- 
- 
 
 
689(97) 
1(<1) 
3(4) 
- 
- 
- 
13(2) 
 
60 (74) 
3 (4) 
2 (2) 
5 (10) 
- 
3 (4) 
8 (10) 
 
229 (68) 
8 (2) 
5 (2) 
37 (11) 
2 (1) 
7 (2) 
32 (9) 
 
2213 (90) 
13 (1) 
20 (1) 
44 (2) 
3 (<1) 
11 (<1) 
159 (6) 
 
 
 
The most frequently administered class of chemotherapy drugs were exfoliants (21%) and inflammitants 
(19%). Eight percent were receiving highly emetogenic treatments. Staff distributing the questionnaires 
reported that patients found completing the section on chemotherapy drugs received difficult either 
because they did not know what drugs they were receiving or because they did not understand why 
their particular chemotherapy drugs were not listed. As a consequence it is possible that this data is 
incomplete. Almost 50% of the sample was receiving cycles 2, 3 or 4 of their chemotherapy treatment 
and the majority were receiving their treatment as an infusion or injection (66%) via a peripheral cannula 
(69%). 
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Table 6.3: Diagnosis and treatment received 
 
 
 
6.1.2 Severity of subjective symptoms  
 
Forty-three per cent of patients reported experiencing moderate or severe nausea though this varied 
across sites (see Chart 6.1). For example, at Centre P 73% reported moderate or severe nausea whilst 
the proportion at Centre J was 24 %. Across the whole sample the proportion reporting no nausea was 
19% however at Centre P there were no patients who did not report this symptom. At the remaining 
centres scores ranged between 17% - 33%. It is possible that these differences could be explained by 
between centre differences in treatment regimens. Moderate or severe vomiting was reported by 21% of 
the whole sample. For six centres the rate of moderate and severe vomiting was 10% or less (see Chart 
6.1). Once again scores for Centre P differed substantially from the other centres with 53% reporting 
moderate or severe vomiting. On the whole there was a large number (approximately 40%) of people 
who said that they had not experienced any vomiting with their previous cycle of chemotherapy. 
Centre  J  K  L  M  N  P  Q  R  S  T  Total 
N   250  30  117  154  191  522  126  737  85  352  2466 
Diagnosis N (%) 
Colorectal 
Breast 
Lung 
Gynaecological 
Other 
                  Missing 
 
8 (3) 
33 (14) 
8 (3) 
15 (6) 
60 (24) 
126 (50) 
 
- 
24 (83) 
- 
- 
- 
5 (17) 
 
13 (11) 
44 (38) 
18 (15) 
2 (2) 
17 (16) 
23 (20) 
 
1 (1) 
32 (21) 
30 (20) 
4 (3) 
59 (38) 
29 (19) 
 
9 (5) 
45 (24) 
34 (18) 
- 
  54 (28) 
49 (27) 
 
40 (8) 
128 (25) 
51 (10) 
39 (8) 
105 (20) 
159 (30) 
 
9 (8) 
24 (21) 
8 (7) 
20 (18) 
49 (39) 
16 (13) 
 
98 (14) 
182 (25) 
39 (6) 
50 (7) 
143 (19) 
225 (32) 
 
25 (31) 
- 
- 
7 (9) 
18 (21) 
35 (41) 
 
5 (2) 
49 (15) 
44 (13) 
18 (5) 
101 (29) 
135 (41) 
 
208 (8) 
561 (23) 
232 (9) 
155 (6) 
508 (21) 
802 (33) 
Received vesicant 
chemotherapy N (%)  
 
39 (16) 
 
3 (10) 
 
2 (2) 
 
17 (11) 
 
8 (4) 
 
50 (10) 
 
30 (27) 
 
84 (12) 
 
5 (6) 
 
57 (17) 
 
296 (12) 
Received irritant 
chemotherapy N (%) 
 
27 (11) 
 
- 
 
17 (15) 
 
44 (29) 
 
32 (17) 
 
155 (31) 
 
24 (21) 
 
99 (14) 
 
18 (22) 
 
54 (16) 
 
470 (19) 
Received exfoliant 
chemotherapy N (%) 
 
41 (17) 
 
5 (17) 
 
5 (4) 
 
11 (7) 
 
17 (9) 
 
128 (25) 
 
35 (31) 
 
129 (18) 
 
28 (35) 
 
118 (35) 
 
517 (21) 
Received inflammitant 
chemotherapy N (%) 
 
17 (7) 
 
14 (48) 
 
27 (23) 
 
30 (20) 
 
35 (19) 
 
89 (18) 
 
15 (13) 
 
103 (15) 
 
26 (32) 
 
29 (9) 
 
385 (16) 
Received highly 
emetogenic chemotherapy 
N (%) 
 
18 (8) 
 
- 
 
27 (23) 
 
30 (20) 
 
35 (19) 
 
89 (18) 
 
15 (13) 
 
103 (15) 
 
26 (32) 
 
29 (9) 
 
193 (8) Nurse Sensitive Indicators   2011 
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Chart 6.1: Nausea and vomiting 
 
 
 
 
 
Moderate or severe oral problems were highly prevalent with 41% reporting it as a moderate or severe 
problem (Chart 6.2). There was variation between centres with the lowest proportion being 27% (Centre 
N) and the highest being Centre P (68%).  
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Chart 6.2: Oral problems 
 
 
 
 
Moderate or severe weakness and moderate or severe unusual tiredness (Chart 6.3), were the most 
commonly reported symptoms, with reported rates of 54% and 67% respectively. At seven centres less 
than 40% rated their weakness as moderate or severe. The scores for Centre P differ as the proportion 
with moderate or severe weakness was 83% and there were no patients who did not experience it.   
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Chart 6.3: Weakness & tiredness 
 
 
 
 
 
Across the whole sample 41% of respondents reported experiencing moderate or severe feelings of 
being low in mood or depressed (see Chart 6.4). There was variability between centres particularly in 
relation to the reporting of severe problems, for which the proportion ranged from 0% (Centre K) to 18% 
(Centre P). Results for Centre P differ from the other centres as more respondents reported feeling 
moderately low or depressed (52%) and there was no one who said they did not experience this 
symptom at all.   
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Chart 6.4: Low or depressed 
 
 
 
 
The proportion reporting they experienced moderate or severe signs of infection (see Chart 6.5) was 
over 10% in all centres (K and P). Rates varied from 12% in Centre S to 56% in Centre P. At Centre P 
there were no respondents who did not experience this symptom at all.  
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Chart 6.5: Signs of infection 
 
 
 
 
Results of the “distress thermometer”, designed to indicate global distress (see Chart 6.6) suggest it is 
not measuring the same construct as that assessed by the feeling low or depressed item as there is a 
smaller proportion (19%) who report moderate or severe distress (0-2). There is less between centre 
variability on this item.  
 
 
Chart 6.6: Distress thermometer 
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6.1.3 Risk adjusted symptoms 
 
Direct comparison between centres requires the assumption that like is being compared with like. 
However, variation in patient characteristics, case mix and drugs used will affect the symptoms 
experienced, irrespective of the quality of care delivered.  
 
Regression-based models were used to adjust for case mix. We calculated a standardised symptom 
ratio (SSR) for nausea, vomiting, mouth problems and overall distress. This is analogous to the widely 
reported „Hospital Standardised Mortality Ratios‟ used by Dr Foster to compare hospital death rates, 
and a similar methodology was used. The standardised symptom ratio is the ratio of the number of 
people reporting moderate or severe symptoms to the number predicted for that centre from a 
regression model. For overall distress, the proportion scoring above the 75th centile (≥5) was modelled.  
 
The predictive variables in Box 6.1 were entered as dependants in a logistic regression analysis and the 
sum of predicted probabilities was used to calculate the expected number of cases. In order to make 
use of all the data, missing values on the following key predictor variables were imputed using multiple 
imputation techniques in SPSS: method of administering treatment, method of receiving treatment, sex, 
age, diagnosis and ethnicity. 99% confidence intervals (99% CI) were estimated using Byar‟s 
approximation to the Poisson distribution. 
 
 
Box 6.1: Variables used to calculate the standardised symptom ratio 
 
Demographics: 
  Age (18-30, 31-40,41-50, 51-60, 61-70, 71+) 
  Sex (male, female) 
  Ethnicity ( White UK, all other categories) 
Clinical 
  Diagnosis (Colorectal, breast, lung, gynaecological, haematology, other cancers) 
Treatment 
  Emetogenic treatments 
  Inflammitant treatments  
  Exfoliant treatments 
  Vesicant treatments 
  Treatment cycle (1, 2-5, 6-7, 7+) 
 
 
A standardised symptom ratio of more than 100% indicates that more patients than would be expected 
were experiencing symptoms, based on the clinical, demographic and treatment characteristics of the 
patients treated. Each centre was ranked according to raw scores and SSR for moderate or severe 
symptoms (rank 1 = highest standardised symptom ratio). For each item the centres unadjusted rank 
order was compared to the adjusted ranking using correlation: the closer the correlation coefficient to 1 
the greater the similarity between the unadjusted and adjusted rankings. 
 
Overall, risk adjustment made relatively little difference to the „ranking‟ of centres in terms of proportion 
of patients experiencing severe or moderate symptoms. Correlations between adjusted and unadjusted 
ranking were high across all items - see Table 6.4. A traffic light colouring system has been applied to 
the ranks, with green indicating lower scores and red higher scores.  
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Table 6.4: Standardised and unstandardised symptom rates 
 
Centre  Rate per 
100 
patients 
Rank  SSR  Rank  Lower CI  Upper CI  Correlation of un-
standardised rank 
and SSR rank 
Nausea               
J  25  10  67%  9  46%  93%  0.90 
K  41  3  82%  5  33%  165%   
L  26  9  60%  10  35%  96%   
M  39  4  82%  4  57%  115%   
N  33  6  74%  8  51%  103%   
P  73  1  160%  1  139%  184%   
Q  38  5  89%  3  57%  131%   
R  43  2  103%  2  88%  119%   
S  32  7  77%  6  42%  129%   
T  29  8  75%  7  56%  97%   
Vomiting               
J  11  5  57%  5  32%  94%  .99 
K  3  10  14%  10  0%  101%   
L  10  7  48%  6  19%  99%   
M  16  3  68%  3  37%  114%   
N  9  8  40%  8  18%  76%   
P  54  1  233%  1  197%  274%   
Q  10  6  47%  7  18%  98%   
R  17  2  83%  2  64%  105%   
S  7  9  33%  9  7%  94%   
T  14  4  66%  4  43%  96%   
Mouth 
problems               
J  28  9  77%  6  55%  105%  .88 
K  34  6  71%  9  26%  151%   
L  44  3  106%  3  71%  153%   
M  47  2  107%  2  76%  145%   
N  27  10  65%  10  43%  94%   
P  69  1  156%  1  134%  180%   
Q  29  7  72%  8  43%  112%   
R  37  5  92%  5  77%  108%   
S  40  4  97%  4  57%  154%   
T  28  8  75%  7  56%  98%   
Distress               
J  26  10  86%  10  61%  119%  .98 
K  28  8  88%  9  28%  204%   
L  31  5  97%  4  59%  150%   
M  38  1  117%  1  79%  165%   
N  30  6  96%  6  65%  135%   
P  28  9  90%  8  71%  112%   
Q  34  2  111%  2  72%  163%   
R  33  3  109%  3  91%  129%   
S  29  7  93%  7  49%  159%   
T  32  4  97%  5  73%  126%   
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Only one centre (P) was a clear outlier, with the standardised symptom ratio being significantly above 
100% for all symptoms except overall distress, indicating that investigation into the cause of the 
difference between this centre and others is warranted. However, two notes of caution should be issued 
here, prior to further discussion of this issue. The relative lack of change in ranks after this procedure 
suggests that the differences observed may not be simply a matter of differences in case mix on the 
variables that we measured. However, the information used to produce the risk adjustment model was 
incomplete and this does not by any means represent the ideal model. Further, since centre P returned 
a large amount of data compared to most others, the fact that most other SSRs are below 100% should 
not give undue reassurance as this really only reflects performance relative to that in Centre P. The 
relative, as opposed to absolute, SSR is probably the best indicator. 
 
 
6.1.4 Support to manage symptoms  
 
These items assess patient‟s perceptions of what nurses do in response to symptoms they experience 
(see Charts 6.7- 6.8). Across the whole sample the majority of patients report that the chemotherapy 
nurses ask about their symptoms (90%), are aware of symptom severity (85%), provide useful 
information (87%) and practical advice for symptom management (87%). However, a significant number 
did not fully agree with these statements and there was large variation between centres. Most 
respondents said they felt confident about managing their symptoms (85%).  
 
Although respondents from Centre P consistently reported more moderate or severe symptoms, ratings 
for the process of symptom management were comparable to the other centres. Conversely, whilst the 
proportion of those with moderate or severe symptoms at Centre J was average or below average, 
respondents rated the nurses lower than other centres on the process of symptom management.  
However, overall and despite the small sample size (10) there was some modest evidence of correlation 
between a centre‟s performance on support to manage symptoms and symptom control (see Table 6.5). 
In particular, centres where more patients believed that nurses were aware of symptoms and provided 
information tended to have patients with better symptom control for vomiting and mouth problems and 
fewer reporting pain at their infusion site.  However global distress did not show a similar relationship. 
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Chart 6.7: Support to manage symptoms (1) 
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Chart 6.8: Support to manage symptoms (2) 
 
 
 
 
 
Table 6.5: Correlations between support and symptoms (centre level n=10) 
 
   Nausea  Vomiting 
Pain at 
infusion site 
Mouth 
problems 
Overall 
distress 
Nurses ask about symptoms  .006  .200  .297  .067  -.406 
Nurses aware of symptoms  .091  .527*  .624**  .479*  -.236 
Nurses give useful information  -.030  .552**  .673**  .430  -.079 
Nurses give practical advice  .109  .207  .340  .097  -.456* 
Confidence in self care ability  .333  .842***  .527*  .212  .079 
*** Correlation is significant at the 0.01 level (1-tailed) 
**  Correlation is significant at the 0.05 level (1-tailed) 
*    Correlation is significant at the 0.10 level (1-tailed) 
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Centre T
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6.1.5 Relationship with 2010 National Patient Experience Survey  
 
Although it is not focussed on nursing the 2010 National Cancer Patient Experience Survey (NPES) [5] 
asks specific questions of those who have been treated with chemotherapy (see Box 6.2). We explored 
the correlation between symptom experience and support data from our nurse-sensitive indicators 
(adjusted ranks for symptoms) with 2010 national survey results for the centres in the study (see Table 
6.6). We correlated the proportion of patients endorsing each item in the 2010 national survey (rank 
score) with the rank of the centre on our indicators.  
 
 
Box 6.2: 2010 National Patient Experience Survey chemotherapy specific questions [5] 
 
 
There was a high correlation between national survey scores on some aspects of symptom experience 
(nausea, vomiting, IV pain and oral problems) and the 2010 NPES questions [5]. However the 
relationship with the nursing support questions was small or non-existent. 
 
 
Table 6.6: Correlations with 2010 National Patient Experience Survey items [5] 
 
  National Patient Experience Survey 
Nurse Sensitive Indicators  Side effects 
(Q56) 
Pain 
(Q57) 
Emotional support (Q58) 
Nausea  -.247  -.602**  -.586** 
Vomiting  -.570*  -.347  -.682** 
IV pain  -.383  -.694***  -.630** 
Distress  -.741**  -.529*  -.769*** 
Ask about symptoms  -.630**  -.091  -.638** 
Aware of symptom severity  .434  -.110  .035 
Useful information  .017  -.329  -.297 
Practical advice  .017  -.274  -.280 
Confidence in self-care  .427  -.257  -.009 
*** Correlation is significant at the 0.01 level (1-tailed) 
**  Correlation is significant at the 0.05 level (1-tailed) 
*    Correlation is significant at the 0.10 level (1-tailed) 
 
Q56: Did hospital staff do everything possible to control the side effects of chemotherapy? 
 
Q57: While you were being treated as an out-patient or day case, did the hospital staff do 
everything they could to control your pain? 
 
Q58: While you were being treated as an out-patient or day case, were you given enough 
emotional support from the hospital staff? Nurse Sensitive Indicators   2011 
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6.1.6 Patient experience  
 
Patients were asked to complete additional items regarding their experience of the process of the 
chemotherapy administration process and informational support once during the data collection period. 
This was a pragmatic decision aimed at reducing the burden on respondents who were being asked to 
complete the outcome measure repeatedly during the data collection period. The rationale for this was 
because responses on these items were generally summative of the entire experience and unlikely 
likely to change much, unlike those assessing chemotherapy-related symptoms and the process of 
symptom management.   
 
Unfortunately the longer version of the outcome measure was inconsistently administered between sites 
due to distribution problems. Thus, small numbers (<50) were returned by most sites and three sites 
(Centres J, P, S) did not return any. Centre T was an exception and returned almost 200 completed 
questionnaires. Despite the small number available for analysis, scores demonstrated some variability 
between sites and between items (see Chart 6.9-6.10). Of 132 respondents taking oral chemotherapy 
11% felt that they had not received a comprehensible explanation of what it involves. The proportion 
was higher at Centre N (34%). The majority (87%) of patients who had needed to contact a 
chemotherapy nurses about a problem reported the nurse had dealt with to their satisfaction. At Centres 
T and Q 7% and 8% respectively felt that the nurses did not sort out their problem and at Centre T 11% 
did not know who to contact. The numbers, however, are very small, and so estimates should be treated 
with some caution. 
 
Chart 6.9: Information from chemotherapy nurses before treatment 
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Chart 6.10: Availability of advice and support during treatment 
 
 
 
 
Although nurses cannot always influence whether patients receive their treatment in a timely fashion 
(e.g. pharmacy delays) waiting an unnecessary amount of time for chemotherapy and feeling treatment 
is rushed can adversely colour patient‟s experience of receiving treatment. However, if a service is 
managed by nurses, managing the problem is potentially a nursing accountability issue. As a 
consequence these items were retained in the outcome measure. From Chart 6.11 it can be seen that 
up to 15% at Centres L, N, Q and T said they always experience unnecessary waiting time. Across all 
the centres 29% reported sometimes experiencing unnecessary waiting time. In terms of whether 
patients felt that their treatment was rushed the majority (88%) said they never felt their treatment was 
rushed. However, at Centres L, Q R and T 4-8 % said their treatment was always rushed and at Centre 
T a further 20% said that it was sometimes rushed. At Centres Q, R & T 10-14% felt chemotherapy 
nurses were not always gentle or skilful at cannulation.  
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Chart 6.11: Experience of the administration process  
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6.1.7 Safety of drug administration  
 
Table 6.7 shows the number of extravasations or suspected extravasations that occurred during the 
data collection period. The rate for the whole sample was 0.7 per 1000 chemotherapy regimen 
administered, though this varied between centres. No incidents of ulceration as a result of extravasation 
were reported during the period of data collection. 
 
Table 6.7: Rate of extravasation 
 
Centre  J  K  L  M  N†  P  Q  R  S*  T 
Data collection (weeks)  12  10  6  6  -  8  6  10  *  9 
Number  3  0  0  0  -  0  0  1  *  1 
Number regimens 
administered 
2464  140  244  187  -  593  706  487  *  2109 
Rate/1000 regimens 
administered 
1.2  0  0  0  -  0  0  2.1  *  0.46 
† = not available  * = combined with Centre T     
 
 
Pain and irritation at the chemotherapy infusion site can be a symptom of extravasation as well as being 
caused by certain chemotherapy drugs. One way to reduce this symptom is to slow the rate at which the 
drugs are administered. Twenty three percent of patients reported this as a moderate or severe problem 
(See Chart 5.12). At nine centres the proportion was less than 20% and the percentage saying they had 
experienced any problems ranged between 27% - 62%. At Centre P, however, 54% reported moderate 
or severe pain at the infusion site and none said this had not been a problem.  
 
 
Chart 6.12: Pain and irritation at the infusion site 
 
 
 
 
As this symptom is likely to be influenced by the drug regimens used we used the method of risk 
adjustment described earlier to take this into account (see Table 6.8). Pain and irritation at the infusion 
site remained high at Centre P after adjustment was made to take account of drug regimens used. 
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Table 6.8: Pain and irritation at IV site 
 
Centre  Rate per 
100 
patients 
Rank   SSR  Rank   Lower CI  Upper CI  Correlation of un-
standardised rank and SSR 
rank 
T  13  9  60%  7  38%  89%  .75 
J  16  5  79%  3  49%  119%   
K  17  4  56%  9  12%  158%   
L  16  6  67%  6  32%  121%   
M  18  3  82%  2  46%  133%   
N  9  10  40%  10  19%  76%   
P  55  1  210%  1  178%  246%   
Q  15  7  71%  5  34%  131%   
R  19  2  79%  4  62%  98%   
S  14  8  58%  8  21%  124%   
 
 
 
6.2. Stakeholder feedback 
 
We conducted telephone interviews with the local project leads at eight participating centres to explore 
their perceptions of the project, the challenges and benefits of participating and to identify any 
improvements they thought should be made. Interviews were anonymised and each person assigned a 
code that corresponds to the centre at which they are employed (for example M1 represents a person 
working at Centre M). All centres were able to identify benefits from the data supplied by the indicators 
and many highlighted that it provided information that was otherwise unavailable to them. Several 
described specific plans to implement change and to use the indicators in future (see Table 6.9). 
 
Whilst not all stakeholders were clear at the outset what the aim of the project was, by the end most 
articulated that it was about „assessing whether patients are getting the support they need whilst 
undergoing chemotherapy to manage side effects‟ (M1). One felt that it would „highlight any areas in 
which the unit is falling short and we could do something about it‟ (R1). Two others identified that a 
component of checking the quality of care is seeing „where it [centre] stood in comparison with other 
sites‟ (Q1) or benchmarking. When asked why they decided to participate most stakeholders clearly 
stated how they were keen to get feedback on patients perception of the care nurses delivered and one 
was particularly keen to establish „that nurses do make a difference to patients experience‟ (M1). One of 
the difficulties previously had been that it was not possible to make comparisons between centres in 
terms of chemotherapy services due lack of data. This was a key selling point for some stakeholders.  
 
Without exception the stakeholders had found participating in the project valuable, despite the inherent 
challenges of data collection. They particularly appreciated having data on their performance and being 
able to judge how well they were doing by comparing themselves to other centres. One commented: 
 
„Information that was returned from the audit; the NCAG, NCPOD reports and the issues these 
highlight have to be brought to the attention of nurses, that the same exists in their unit, i.e. the 
issues aren‟t just remote. It ties national documents to the local experience.‟ (T1) 
 
Another commented that the data provides another part of the informational jigsaw, and can help make 
sense of other data, such as that from the National Cancer Patient Experience Survey [5]. Some of the 
results were similar to those from this project, but the former results were not specific to chemotherapy Nurse Sensitive Indicators   2011 
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nurses. Thus the data from the nurse sensitive outcomes indicators provided some of the detail that 
may, to some extent, explain the patient survey results. It „puts some meat on the bone‟ (J1) 
 
Having the data was seen as beneficial, even if the results were less encouraging than they had hoped 
for: 
 
„Finding out there seemed to be a lot more patients experiencing symptoms than we had 
anticipated‟ (Q1) 
 
„I was shocked by interim report data suggesting 10% of patients reporting pain and irritation at 
the site‟ (P1) 
 
Nevertheless P1 then goes onto say that participating was a valuable experience as „data about 
symptom management would not have been collected otherwise‟.  
The majority felt that the way the interim results were presented was helpful. One person commented  
„Happy with format of information. Charts using the mean deviation, as used in the NHS outpatient 
experience report is a confrontational way of presenting data. NHS managers focus on getting above 
this mean.‟ (S1) 
 
 Most planned to use the information to make changes to care delivery, as illustrated by the following 
examples: 
 
„The unit has changed anti-emetic treatments recently, but when the final results are available 
we will definitely look at the treatments again‟ (Q1) 
 
„I took it to a staff meeting and flagged up the extent of lethargy and fatigue which should not be 
underplayed. Also I want to look at what can be done regarding nausea and vomiting, but hope 
that this will improve as we are going to enforce some nausea and toxicity scoring in the clinic 
as part of NCAG. Nurses don‟t see patients in clinic, so are wanting to know what patients are 
saying to doctor and if doctor is picking up on what the patient is saying. I think that this action 
will make things better and will be in place soon.‟ (P1) 
 
„We have decided to make changes to practice in response to the finding about whether 
chemotherapy nurses are asking about symptoms. On the pre-assessment before patients start 
chemotherapy, we will start telling patients that they will be asked about certain problems, so 
they know it‟s going to happen and it‟s in their mind. Because at the moment although it is 
documented that nurses ask about symptoms, maybe patients don‟t realise that we‟re scoring 
the toxicities by asking them. Tell the patients that we‟re asking them for a reason and so they 
don‟t just think its general chit chat. It also brought to light the number of patients who didn‟t 
know what drugs they were on despite being given a hand-held diary with the drugs written in 
it.‟ (R1) 
 
The majority of the stakeholders interviewed said that they would use the nurse-sensitive indicators 
routinely in practice. However, they stressed that they felt that it would be more beneficial to use it 
intermittently, such as 3 or 6 monthly, and over a shorter data collection period, 3-8 weeks, to overcome 
some of the difficulties outlined above. Whilst one person felt that it would be useful to use it with 
patients at the midpoint in their course of treatment as by then many would be symptomatic, they 
recognised that identifying all eligible patients may make data collection more problematic. Another was 
considering using the measure at the end of treatment when patients would be able to review their 
experiences.  Nurse Sensitive Indicators   2011 
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Table 6.9: Local implication of results identified by stakeholders 
 
Centre  Implications of results  Future plans 
J  Need to be more proactive about side effects 
Review current patient information booklets 
Explanations for symptom severity questions 
1.  nurses not systematically asking patients 
2.  nurses have insufficient knowledge base 
 
 
K  See what is working well and ways to improve 
 
 
L  Can compare experience of those having chemotherapy 
with other more general local audits of patient 
experience 
 
 
M    Would include NSI in future audits 
 
N   No other audits conducted in unit therefore useful to 
have results 
 
 
P  What measures or improvements can be made to 
patients experience of pain and irritation at IV site – 
more proactive assessment and explanation to patients 
Increased awareness of fatigue and lethargy and impact 
made on patients experience 
What measures or improvements can be made to 
improve experience of nausea and vomiting 
 
Use NSI into end of treatment assessment – pilot and adapt 
NSI to explore if and at which point patients were given 
relevant information and whether symptoms were managed 
appropriately 
 
Review anti-emetic protocol and use NSI again to identify 
drugs causing the most emesis problems. 
Introduce nausea and vomiting toxicity assessment by 
nurses 
Q  More than anticipate patients experiencing symptoms  Anti emetic protocol recently changed will review in light of 
NSI results 
R  What can be done to improve patients perceptions of 
nurse assessment of symptoms 
Large number of patients do not know what 
chemotherapy drugs they were receiving despite being 
recorded on patient-held diary 
What can be done to reduce the unexpectedly large 
number experiencing nausea 
At pre-assessment will inform patients that symptoms will be 
systematically assessed at each treatment cycle 
 
Review anti-emetic protocol so medication started the day 
before chemotherapy administered. Use NSI to monitor 
whether it results in improvements 
 
T*  NSI is an excellent method for assessing nursing service 
Ties national documents (NCAG, NCEPOD, NPES) to 
local experience 
Need formal assessment of treatment toxicities by 
nurses  
Nurses need to improve recording of assessment 
Introduce multidisciplinary (nurses, doctors, pharmacists) 
pre-treatment consultation particularly for oral chemotherapy 
Introduce multidisciplinary (nurses, doctors, pharmacists) 
clinic for on-treatment patients 
NSI = Nurse sensitive indicators  * = Centre S combined with Centre T 
 Nurse Sensitive Indicators   2011 
 
37 
 
A number of issues were raised about the process of data collection and these are as follows: 
  data collection was seen as being arduous and time consuming and if it was to be done 
properly it needed to be supervised by the local project lead 
  Nursing staff need to buy into the project rather than relying on reception staff to run the 
project 
  The contextual data was difficult to collect as it was not readily available in management 
systems 
  Many patients experienced questionnaire fatigue and chose not to complete the measure 
on multiple occasions. Some centres noted that this could be overcome if nurses were 
more involved and explained the rationale for completing it more than once 
 
This feedback along with information collected during data collection has been used to revise the toolkit 
for centres using the self-report/self-assessment questionnaire (See Appendix J). 
 
Some reported that the questionnaire was overly „clinical‟ and this was reinforced by the long list of 
chemotherapy drugs at the beginning. The list was not felt to be comprehensive and it may be more 
useful to collect information on what regimen people were receiving rather than focusing on the specific 
drugs. The extensive instructions at the beginning were seen as being somewhat off-putting. One centre 
preferred the long version of the measure (incorporating additional experience items) as it provided 
more information. Nurse Sensitive Indicators   2011 
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7. Discussion 
 
This project has successfully developed and tested a suite of nurse-sensitive indicators that could 
contribute to the effective monitoring of chemotherapy services. The indicators cover  
  severity of subjective symptoms resulting from treatment, across a range of domains, 
including those that we identified as most sensitive to the quality of nursing services (nausea, 
vomiting, oral problems) 
  perceptions of assessment, information and support to manage symptoms offered to patients 
by nurses who administer chemotherapy (support for self-care) 
  safety of drug administration (extravasation and pain at infusion site) and  
  patient experience of the administration process and informational support.  
 
 
7.1 Severity of subjective symptoms 
 
Our results show that substantial numbers of patients are experiencing distressing symptoms and there 
is variability between the centres that we studied in both perceived support from nurses and patients‟ 
subjective symptom severity. While the most prevalent symptoms (weakness and tiredness) were not 
ones which our review [6] had clearly supported as sensitive to the quality of nursing, there were 
substantial numbers of patients experiencing the symptoms which were most likely to be nursing 
sensitive and substantial variation between centres. For example, overall, 43% of patients experienced 
moderate or severe nausea but the figure varied across centres, from 24% to 73%. When we adjusted 
for case mix, large amounts of variation remained, although only one centre was clearly an „outlier‟, with 
significantly higher numbers of patients reporting moderate or severe symptoms than would be 
expected, based on our statistical models. 
 
Symptoms are largely a product of the chemotherapy regimen administered, the supportive care 
provided and individual variation. In the analysis here, we were able to explore the effect of diagnosis, 
chemotherapy cycle and drugs used, which should be helpful in allowing units to benchmark their 
performance. The low number of outliers (albeit in a small sample of centres) provides some evidence 
that the indicators are valid measures of quality. Any indicator system which yields a large number of 
outliers may simply be reflecting inadequate risk adjustment or an indicator which is not sufficiently 
sensitive to quality to be useful [18]. However, although the results give some confidence, our risk 
adjustment model was, of necessity, limited. There remains the possibility that the variation in response 
rate was an important contributor to the differences between centres. There was little evidence of 
positive correlations between the levels of adverse symptoms and response rates from centres, as 
would be found if response was biased toward patients who were experiencing less distressing 
symptoms. However the small sample size and the absence of a precisely defined sampling frame in 
the pilot sites makes further exploration of this issue difficult.  
 
Despite some encouraging findings, based on the validation work undertaken so far, it is difficult to use 
direct comparisons between centres to make judgements about relative quality of services. Further work 
is needed in order to adjust levels of reported symptom severity for differences between regimens and, 
if necessary, characteristics of the individual patients. Collecting the information required for this from 
individual patients at each attendance was burdensome. To make further progress with this, fuller 
linkage to patient records, including full demographic details and precise chemotherapy regimen, which 
was beyond the scope of this project, is required. We believe this data will be available in the national 
chemotherapy minimum dataset. This raises significant issues about how the information should be 
gathered from patients and used in practice, to which we will return to later. Nurse Sensitive Indicators   2011 
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We initially intended to pilot indicators derived from those symptoms and issues that our review had 
given us most confidence their about sensitivity to nursing. During development we added a number of 
symptoms to our initial short list, as their absence made the self-assessment questionnaire seem 
incomplete and, implicitly, appeared to be disregarding other important symptoms. The addition of these 
symptoms seemed feasible and patients had the opportunity to add others on completing the self-report 
instrument. However, we remain unsure as to whether these symptoms, derived from the widely used 
Chemotherapy Symptom Assessment Scale [13] (tiredness, weakness, fatigue and signs of infection) 
are ideal candidates as nurse sensitive outcome indicators because of the limited evidence available for 
effective interventions[6]. The extremely high rates of “signs of infection” (100%) in one centre raises 
questions about this as an indicator of „symptom experience‟. Responses to this could be influenced by 
successful education about likely signs of infection while actual symptoms experienced were similar and 
ultimately, the presence or absence of infection is not a subjective experience. 
 
 
7.2 Support to manage symptoms 
 
In addition to the variation in symptoms, perceived support from chemotherapy nurses to manage 
symptoms was also variable. For example while overall 90% of patients  answered „yes‟ to the question 
„do nurses ask you about your symptoms‟ the range was from 97% to as low as 72%.  Similarly the 
numbers answering „yes‟ to the question about nurses providing practical advice varied from 69% to 
94%. This variation in support reflects the results of the National Cancer Patient Experience Survey [5]. 
The national survey showed that, in some trusts, as few as 60% of patients felt that staff did everything 
possible to control side effects of chemotherapy (compared to 95% in the best).  
 
There were strong correlations between results from the national patient experience survey and 
symptom severity in our ten centres. This applied particularly to those symptoms that we had identified 
as having strongest evidence of sensitivity to nursing and gives a clear indication that there may be 
validity in the results. For the items most strongly associated with nursing (nausea, vomiting, IV pain and 
oral problems) we also found some evidence of an association with perceived support from 
chemotherapy nurses, although it was weaker than the evidence for association with the National 
Cancer Patient Experience Survey [5] results. Although there were some associations between the 
results of the national survey and our specific items about nursing awareness and support, the 
correlations observed in this small sample were not significant and were typically negligible. No clear 
pattern appeared suggesting that the items are largely independent of one another. Because of the 
small samples involved we are wary of speculating too much on the specific pattern of results, but 
broadly these associations give some support to the validity of the indicators as being nurse sensitive, 
while indicating clearly that much more data is required to come to firm conclusions. 
 
There is evidence from the NHS annual inpatient survey and other similar surveys that there are 
systematic differences in response patterns between different patient groups (for example by age, sex, 
educational level and severity of illness). This means that comparisons between services may still need 
to be adjusted to ensure that results reflect differences between services provided, not just differences 
in the people who use them [19, 20]. The NHS National patient survey programme standardises results 
for demographic (age, sex) differences between trusts [15]. However since the views of an individual 
reflect their own experiences, such issues are secondary when identifying areas for improvement and 
issues experienced by patients actually using a service. Therefore we did not attempt to standardise 
data in this project. However it may be that further work is required if a direct measure of relative Nurse Sensitive Indicators   2011 
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performance is required and the fact that we did not standardise responses may account (in part) for the 
absence of any real evidence of correlation with the national survey results. 
 
 
7.3 Safety of drug administration 
 
We collected two indicators of safe drug administration. A large number (23%) reported moderate to 
severe pain or irritation at the infusion site with rates varying by site from 8% to 54%. Adjustment for the 
effect of diagnosis, chemotherapy cycle and drugs used showed one centre with a higher than expected 
ratio of observed to expected symptoms, suggesting that the differences are not simply a product of 
differences in regimens. However the cautions noted above about risk adjustment models apply here. 
We gathered data about extravasation rates from nine of our ten centres, suggesting that monitoring is 
feasible but we were unable to determine if there was any association with the patient reported indicator 
of pain and irritation. The number of incidents is low, and considerably more data would be required for 
any conclusion to be drawn. The rate of suspected / actual extravasations was such that none were 
reported in most centres. This indicator is also potentially biased by variation in surveillance and the 
index of suspicion used. No incidents of ulceration due to extravasation were reported and it is likely that 
this will be a sufficiently rare event to not prove useful as a routine indicator for comparison purposes, 
although clearly any incident warrants investigation. 
 
 
7.4 Patient experience 
 
We explored additional aspects of patient experience in a format designed to be administered at a 
single point during treatment. The items selected were all endorsed widely by our advisory groups and 
the service users we interviewed. Items related to experience of the administration process and 
information support offered prior to and during therapy. We strove to avoid overlap and repetition of 
items in the national experience survey and so focussed on specific items about the process of care in 
ambulatory chemotherapy. Because of the intermittent nature of distribution of the questionnaire (once 
during the survey period), and logistical problems experienced in the centres, the number of responses 
we received to this was low and most centres returned too few to warrant meaningful comparisons.  
 
However, the responses obtained suggest that these items do cover issues that are of concern with 
some indication of variability in the experience of patients. In particular large numbers of patients in 
most centres (40% overall) said they sometimes or always waited an unnecessary amount of time for 
their chemotherapy. Inclusion of this item was relatively controversial, as members of the clinical 
reference group pointed out that reasons for delay were often not directly responsible for delays. 
However, the issue was so strongly endorsed in our interviews with service users that we retained the 
item (dropping the more specific question about being treated within 30 minutes). If a clinic is managed 
by nurses, the organisation of services, management of patient flow and information about processes is 
a nursing accountability issue, even though the service is delivered by a multidisciplinary team.  
 
 
7.5 Utility and feasibility 
 
The majority of information was gathered through patient self-report at the point of chemotherapy 
delivery. This mechanism was shown to be feasible and acceptable to patients. High response rates can 
be achieved, but not all centres were able to do this. In order to gather information to permit adjustment 
of results for underlying risk (e.g. treatment regimen, diagnosis) we gathered information from patients. Nurse Sensitive Indicators   2011 
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However, repeated questioning on these issues did not seem to be acceptable and response rates were 
adversely affected. We briefly tested an abbreviated form of the self-report instrument which did not 
include the personal information. This appeared to increase responses in the short term and was 
certainly a simpler instrument to complete. 
 
Centres found the feedback from the indicators a useful adjunct to more general feedback from the 
National Cancer Patient Experience Survey [5] and some have already developed plans to act on 
results and to continue using the Indicators. Managers of the services involved testified to the 
usefulness of having the information provided by the indicators available to them. They were able to 
articulate how it was useful in both confirming issues that they were aware of, but also highlighting 
things that they were not aware of (see Box 6.1). A number of centres have used results to identify 
problems, develop action plans including plans to repeat. Evidence from our reviews suggested that 
nursing may provide a solution to sub optimal symptom control in a number of areas, but it should not 
be assumed that the difference is necessarily the result of differences in the quality of nursing care. As 
an example, prescribing practices differ between centres and the availability of more expensive 
antiemetic agents, such as Aprepitant, is sometimes limited. Managers of services were aware of this 
issue and were keen to know more about other centres in order to pick the most appropriate 
benchmarks to compare themselves with and to learn from other centres. Our ability to gather useful 
and meaningful contextual data from centres was limited in this study. Centres were inconsistent in 
provision of staffing and some other contextual information.  
 
While benchmarking is important, any unit has the ability to use these indicators to explore variation in 
their performance over time, as has been planned by some centres. The level of symptoms experienced 
by patients is a significant issue which warrants attention and investigation, as is the perception of 
patients that they are not being properly assessed and supported. The results of the indicators can 
prompt service managers and individual practitioners to question their own practice, seek explanations 
for any apparent deficits and, if appropriate, to identify and evaluate the effects of change.  
Comparisons between centres may usefully stimulate the question as to why they differ even where 
appropriate benchmarks are unclear. Risk adjusted (standardised) comparisons such as those we have 
presented can give further incentive to investigate underlying causes of difference.   
 
Box 7.1: Using the indicators to gain insight 
 
 
“We knew that we were not always formally assessing symptoms but we were surprised by the levels of 
nausea and vomiting reported. We also thought that the information that we were giving was good but it 
seems clear that something isn‟t working well for the patients. This sort of feedback is valuable because 
it is more specific and detailed than the national survey and, importantly, it relates to the particular unit 
that care was delivered in, not the trust as a whole.” Quote service manager centre J 
 
 
 
7.6 Developments and next steps 
 
We designed a system that collected data from patients as they attended for chemotherapy, which 
allows for data collection to be integrated into routine practice rather than as a separate survey 
undertaken intermittently. Feedback from stakeholders was supportive but tended to point toward 
intermittent data collection as opposed to routine use. In Box 6.2 we discus key options for future 
deployment. Nurse Sensitive Indicators   2011 
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As currently implemented the patient self- report element is administered in a paper and pencil „form‟. 
This delivers significant advantages for administration in terms of simplicity and flexibility and is optimal 
for piloting an instrument under development. However, it does little to facilitate data linkage, which is 
important for risk adjustment, or indeed data handling at all. Based on our early piloting we targeted 
reception staff as the key point of distribution, but this did little to facilitate integration into practice. 
 
Our approach was manual data entry, which was contracted out to a specialised provider. This had the 
advantage of flexibility but was also cheaper, given the relatively high start-up costs for preparing paper 
questionnaires for machine reading. Automated input of questionnaires is not a panacea and a step 
change in efficiency can only occur with direct data input. Technology certainly exists that would allow 
direct input onto handheld / tablet PCs and this is routinely used in a number of settings. Again this is 
not without challenges. Nevertheless we acknowledge electronic data collection methods are preferable 
in the long run.  
 
A sensible compromise, which would allow the integration of the indicator collection into routine care, 
may be for core outcome indicators to be inputted directly by nurses into electronic records or e-
prescribing systems with other data collected intermittently (say every 3-6 months) to elucidate 
underlying processes and patient experiences. It would be preferable if data on risk factors (e.g. 
regimen and personal characteristics) were collected from records rather than relying on self-report as 
this does not seem compatible with integration into routine practice. However abbreviated risk factor 
information could be directly inputted by staff if the system were implemented in an electronic format. 
Whilst the scope for data linkage was limited for this project, it is likely that that this is more of a 
possibility if conducted as locally initiated projects. 
 
However to realise the benefits of this system it is vital that there is genuine ownership by staff in the 
ambulatory chemotherapy settings. Our findings showed how commitment of staff is required and that 
patient understanding of the purpose of repeated measurement could increase when it was perceived to 
be owned by nurses.  This is consistent with evidence on „self-assessment‟ measures more generally 
which were seen as acceptable and valuable by patients primarily when it was seen as something that 
was an integral part of clinical care and supported by health professionals, not simply a burden passed 
from practitioners to patients[21].  
 
The comparison to „self-assessment‟ opens up the possibility that the process of gathering information 
to populate these indicators can feed directly into clinical care. There are already a number of 
assessment tools in use which allow patients to self-report the subjective severity of symptoms as 
opposed to the objective toxicities rated by systems such as the National Institute for Health‟s Common 
Toxicities Criteria. These include the Chemotherapy Symptom Assessment Scale [13] which is widely 
used and upon which we based our symptom assessment.  Our experience in the implementation sites 
suggests that use of these tools at the point of delivery of chemotherapy is variable.  Research in 
primary care suggests that giving the patients an opportunity to reflect on and record problems they are 
having prior to seeing a health care practitioner has the potential to improve the quality of interaction 
and perception of the quality of health care delivered [22]. Nevertheless the key to success is that 
clinicians respond to the problems identified.  Nurse Sensitive Indicators   2011 
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Box 7.2: Options for the future 
 
Option  Pros  Cons 
Method of Administration 
Paper and pencil 
administration 
Simplicity, start up cost, flexibility, 
opportunity to use in clinical 
practice 
Data handling burdensome, lack of 
integration with practice, no automatic 
record linkage 
Tablet PC or equivalent  Reduced data handling burden  Initial expense, logistical challenges, 
limited opportunity to „share‟ results with 
nurses, no automatic record linkage, 
unlikely to accommodate all items, 
systems of care may be dictated by 
technology 
E-Prescribing systems at the 
point of care 
Potential direct impact on the care 
process, reduced data handling 
burden 
May be removed from point of 
administration so limited ability systems of 
care may be dictated by technology, 
logistical challenges, loss of control over 
content 
Timing 
Continuous  Potential for integration into routine 
practice and use to guide patient 
care, positive impact on care 
processes (assessment), potential 
for rapid feedback on performance 
Resource intensive unless integrated with 
automated data gathering. 
Intermittent (episodic)  Compatible with more options for 
administration. Less resource 
intensive 
Unlikely to be worth the cost of integrating 
into e systems. Effort required is 
intermittent so some „start up‟ costs are 
repeated. Requires flexible deployment of 
resource 
Personnel 
Administrative staff  Can be integrated into other 
administrative tasks 
Lack of ownership by patients and clinical 
staff, just collecting data 
Chemotherapy nurses  Ownership and commitment by 
nurses and patients required and 
facilitated 
Requires integration into routine practice 
to realise the benefit and significant 
change management, potentially 
burdensome 
Other clinical staff (e.g. pre 
assessment) 
Ownership by patients and clinical 
staff facilitated 
Feedback to chemotherapy nurses may be 
reduced. 
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Discussion of implementing our indicators as part of (or deriving them from) a clinical intervention 
involving self-assessment is, perhaps, moving beyond our brief. In any event it is important that the end 
goal of collecting the data is not simply to possess it. If the information is not used it is hard to justify the 
effort and expense collecting it. Rather the point is to make use of it to benefit patient care. If the 
information collected is not seen to be used, the necessary commitment from both staff and patients is 
unlikely to be sustained.  
 
We struggled to gather information on workforce characteristics and deployment that were identified as 
important contextual factors in our previous work and by our advisory groups. Additional and more 
structured information, for example standardised descriptions of workforce inputs and clinic 
organisation, should be developed. While some of this information may be available from the CQuINS 
peer review the organisation of this around tumour groups means that some cross cutting elements of 
the service, such as organisation and delivery of ambulatory chemotherapy administration, may well be 
relatively „invisible‟ within such audits. However, this information is helpful in interpreting and explaining 
the results of the indicators but its absence does not undermine the results.  
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8. Conclusion 
 
We would recommend the following adaptations to the content of the self-report instrument: 
 
  A single version of the self-report instrument suitable for use at any point in the cycle of 
chemotherapy 
  Therefore the summative patient experience items should be dropped and incorporated into 
intermittent local patient experience surveys with content determined by service users and local 
practitioners. 
  For local (single centre) centre use the abbreviated version (without patient detail) [items B1-B4 
only  
  To permit benchmarking, detail on patient factors and drugs (sections A&C) are required but 
could be derived from other sources of data to deliver core information on: 
o  Cycle number 
o  Drug toxicities 
o  Diagnosis 
o  Mode of administration 
o  Age 
o  Sex 
o  Ethnicity 
 
Because the core symptom assessment were derived from the commonly used Chemotherapy 
Symptom Assessment Scale [13] the indicator can be derived from other data sources and 
assessments that might be routinely undertaken. We would recommend and encourage the 
development of a benchmarking database based on the results of these indicators. Data would need to 
be supplied to a defined standard and definition but local centres could make their own decisions on 
implementation.  
 
The system that we have designed and reported here has real potential to be used now for local quality 
improvement efforts and for benchmarking between centres. We have shown substantial levels of 
adverse symptoms, large numbers of patients who perceive that support to manage symptoms could be 
better and unexplained variation between centres which all suggestion potential for improvement. 
Stakeholders in our pilot sites gave a clear indication of the potential to use these indicators to stimulate 
and evaluate quality improvement. 
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